Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 9:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 245 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Needle-Syringe Clear all

Conditions: Castration-resistant Prostate Cancer, Metastatic Prostate Cancer, Prostate Cancer
Interventions: Testosterone cypionate, Nivolumab; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 3
States / cities: San Francisco, California • Baltimore, Maryland • Boston, Massachusetts

Conditions: Dense Breasts
Interventions: Denosumab, Placebo, Calcium, Vitamin D3, Core needle biopsy, Blood draw; Drug · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 40 Years and older · Female only
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Radius Fracture Distal, Hematoma, Lidocaine, Pediatrics
Interventions: Lidocaine 1% Injectable Solution; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 5 Years to 17 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency
Interventions: Lonapegsomatropin, Placebo, Somatropin; Drug · Other
Lead sponsor: Ascendis Pharma Endocrinology Division A/S; Industry
Eligibility: 23 Years to 80 Years
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 23
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 18 more

Conditions: Macular Edema, Branch Retinal Vein Occlusion
Interventions: Faricimab, Aflibercept, Sham Procedure; Drug · Procedure
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 553 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 39
States / cities: Phoenix, Arizona • Tucson, Arizona • Campbell, California + 36 more

Conditions: Fibromyalgia, Nociplastic Pain
Interventions: Vestibulocortical Stimulation; Procedure
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Medication Adherence, Substance Abuse, Intravenous, Risk Behavior, Hepatitis A, Hepatitis B, Hepatitis C
Interventions: Hepatitis A & B vaccine, Outreach, AIC, SEP; Biological · Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 14 Years to 29 Years
Enrollment: 546 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Influenza, Human
Interventions: Influenza Vaccine; Biological
Lead sponsor: PharmaJet, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 985 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 6
States / cities: Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more

Conditions: Diabetic Macular Edema
Interventions: KSI-301, Aflibercept, Sham Procedure; Drug · Other
Lead sponsor: Kodiak Sciences Inc; Industry
Eligibility: 18 Years and older
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 48
States / cities: La Jolla, California • Redlands, California • Santa Maria, California + 44 more

Conditions: Rib Fractures, Rib Fracture Multiple
Interventions: Bupivacaine, Fentanyl, morphine, hydromorphone, hydrocodone, acetaminophen, ketorolac, gabapentin, ketamine, ibuprofen; Drug
Lead sponsor: Andrew A Herring; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Oakland, California

Conditions: Uveitis, JIA
Interventions: Adalimumab, Placebo; Biological · Other
Lead sponsor: Nisha Acharya; Other
Eligibility: 2 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 11
States / cities: Sacramento, California • San Francisco, California • Aurora, Colorado + 8 more

Conditions: Neovascular Age-related Macular Degeneration
Interventions: Faricimab, Sham Procedure, Anti-VEGF Therapy; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 50 Years and older
Enrollment: 1,036 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 85
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 75 more

Conditions: Myofascial Pain, Myofascial Trigger Point Pain
Interventions: 1% plain lidocaine and 0.25% plain bupivacaine; Combination Product
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Wet Macular Degeneration
Interventions: Faricimab, Aflibercept, Sham Procedure; Drug · Procedure
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 50 Years and older
Enrollment: 658 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 41
States / cities: Phoenix, Arizona • Mountain View, California • Sacramento, California + 36 more

Conditions: Influenza, Seasonal Influenza
Interventions: VRC-GENADJ0110-AP-NV (Adjuplex), Flucelvax, VRC-FLUMOS0111-00-VP (FluMos-v1); Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Lateral Epicondylitis (Tennis Elbow)
Interventions: Platelet Rich Plasma (PRP) Injection, Whole Blood Injection, Dry Needle Fenestration, Sham Injection; Other
Lead sponsor: McMaster University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2023
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Breast Abscess
Interventions: Standard of care breast abscess drainage, Methylene Blue, Lipid Emulsion, Insertion of optical fiber, Laser illumination, Photodynamic therapy; Procedure · Drug · Device
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Opioid Dependence
Interventions: Buprenorphine Extended Release, Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets); Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 60 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Postdural Puncture Headache
Interventions: Epidural Blood Patch, Sphenopalatine Ganglion Block; Device · Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 13 Years to 92 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 2
States / cities: New Brunswick, New Jersey

Conditions: Gestatiaonl Diabetes Mellitus, Pregnancy, Diabetes in Pregnancy, Insulin Dependent Diabetes Mellitus, Insulin
Interventions: Injection Port for Insulin Administration, Single-Use Insulin Needles; Device
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Scleroderma, Systemic
Interventions: GSK2330811, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 6
States / cities: Los Angeles, California • Stanford, California • Chicago, Illinois + 3 more

Conditions: Lumbar Spine Surgery
Interventions: Group 1 - Lumoptik BrightPoint Epidural Device; Device
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 99 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections
Interventions: Background ARVs, PI, enfuvirtide [Fuzeon]; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 32
States / cities: Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 25 more

Conditions: Pain, Anxiety
Interventions: Virtual Reality, Standard Procedure Thyroid Biopsy, Standard Procedure PICC Placement; Device · Procedure
Lead sponsor: Temple University; Other
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

COMbination of Bipolar Androgen Therapy and Nivolumab

RANKL Inhibition and Mammographic Breast Density

Systemic Absorption of Lidocaine After Hematoma Block

A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion

Vestibular Innovation in Pain 2

A Randomized Trial of Vaccine Adherence in Young Injection Drug Users

Inactivated Influenza Via Jet Injection

A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)

US-guided SAPB for Rib Fractures in the ED

Adalimumab in JIA-associated Uveitis Stopping Trial

A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

Investigating the Minimum Number of Needling Required to Optimize Trigger Point Injections Outcome

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)

First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV in Healthy Adults

Comparison of Platelet Rich Plasma and Alternative Therapies for the Treatment of Tennis Elbow (Lateral Epicondylitis)

A Phase 2 Study of Methylene Blue Photodynamic Therapy for Treatment of Breast Abscesses

XRB vs. SLB in Jail and at Re-entry: Pilot, Proof of Concept

Therapeutic Epidural Patch Versus Pain Block in the Midface for Headache

Injection Ports vs Single-Use Needles for Insulin in Pregnancy: Effects on Adherence and Satisfaction

Proof of Mechanism Study of GSK2330811 in Diffuse Cutaneous Systemic Sclerosis

Lumoptik BRIGHTPOINT Reflectometer Device for Lumbar Epidural Placement

BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.

Virtual Reality for the Management of Pain and Anxiety for Outpatient Interventional Radiology Procedures